These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 32439360)

  • 21. Airway Delivery of Anti-influenza Monoclonal Antibodies Results in Enhanced Antiviral Activities and Enables Broad-Coverage Combination Therapies.
    Vigil A; Frias-Staheli N; Carabeo T; Wittekind M
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32847855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potency of whole virus particle and split virion vaccines using dissolving microneedle against challenges of H1N1 and H5N1 influenza viruses in mice.
    Nakatsukasa A; Kuruma K; Okamatsu M; Hiono T; Suzuki M; Matsuno K; Kida H; Oyamada T; Sakoda Y
    Vaccine; 2017 May; 35(21):2855-2861. PubMed ID: 28431812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Formulation of microneedles coated with influenza virus-like particle vaccine.
    Kim YC; Quan FS; Compans RW; Kang SM; Prausnitz MR
    AAPS PharmSciTech; 2010 Sep; 11(3):1193-201. PubMed ID: 20676947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection.
    Kim MC; Lee JW; Choi HJ; Lee YN; Hwang HS; Lee J; Kim C; Lee JS; Montemagno C; Prausnitz MR; Kang SM
    J Control Release; 2015 Jul; 210():208-16. PubMed ID: 26003039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quadrivalent Influenza Vaccine-Induced Antibody Response and Influencing Determinants in Patients ≥ 55 Years of Age in the 2018/2019 Season.
    Ganczak M; Dubiel P; Drozd-Dąbrowska M; Hallmann-Szelińska E; Szymański K; Brydak LB
    Int J Environ Res Public Health; 2019 Nov; 16(22):. PubMed ID: 31739554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fabrication of microneedle patches with lyophilized influenza vaccine suspended in organic solvent.
    Kim YC; Lee JW; Esser ES; Kalluri H; Joyce JC; Compans RW; Skountzou I; Prausnitz MR
    Drug Deliv Transl Res; 2021 Apr; 11(2):692-701. PubMed ID: 33590465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of zymosan and poly (I:C) adjuvants on responses to microneedle immunization coated with whole inactivated influenza vaccine.
    Shin JH; Noh JY; Kim KH; Park JK; Lee JH; Jeong SD; Jung DY; Song CS; Kim YC
    J Control Release; 2017 Nov; 265():83-92. PubMed ID: 28890214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity of influenza vaccine in elderly people: a systematic review and meta-analysis of randomized controlled trials, and its association with real-world effectiveness.
    Meng Z; Zhang J; Shi J; Zhao W; Huang X; Cheng L; Yang X
    Hum Vaccin Immunother; 2020 Nov; 16(11):2680-2689. PubMed ID: 32347787
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy of vaccination of pigs with different H1N1 swine influenza viruses using a recent challenge strain and different parameters of protection.
    Van Reeth K; Labarque G; De Clercq S; Pensaert M
    Vaccine; 2001 Aug; 19(31):4479-86. PubMed ID: 11483274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stability of influenza vaccine coated onto microneedles.
    Choi HJ; Yoo DG; Bondy BJ; Quan FS; Compans RW; Kang SM; Prausnitz MR
    Biomaterials; 2012 May; 33(14):3756-69. PubMed ID: 22361098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of Waning Immunity at 6 Months after Both Trivalent and Quadrivalent Influenza Vaccination in Korean Children Aged 6-35 Months.
    Lee JH; Cho HK; Kim KH; Lee J; Kim YJ; Eun BW; Kim NH; Kim DH; Jo DS; Kim HM; Kim YK
    J Korean Med Sci; 2019 Dec; 34(46):e279. PubMed ID: 31779056
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced Immune Responses Conferring Cross-Protection by Skin Vaccination With a Tri-Component Influenza Vaccine Using a Microneedle Patch.
    Zhu W; Li S; Wang C; Yu G; Prausnitz MR; Wang BZ
    Front Immunol; 2018; 9():1705. PubMed ID: 30105019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of immunogenicity between intradermal and intramuscular injections of repeated annual identical influenza virus strains post-pandemic (2011-2012) in COPD patients.
    Chuaychoo B; Kositanont U; Niyomthong P; Rittayamai N; Srisuma S; Rattanasaengloet K; Wongsrisakunkaew W; Thongam J; Songserm T
    Hum Vaccin Immunother; 2020 Jun; 16(6):1371-1379. PubMed ID: 31770051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single-replication BM2SR vaccine provides sterilizing immunity and cross-lineage influenza B virus protection in mice.
    Moser MJ; Hatta Y; Gabaglia C; Sanchez A; Dias P; Sarawar S; Kawaoka Y; Hatta M; Neumann G; Bilsel P
    Vaccine; 2019 Jul; 37(32):4533-4542. PubMed ID: 31280945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insertion-responsive microneedles for rapid intradermal delivery of canine influenza vaccine.
    Choi IJ; Kang A; Ahn MH; Jun H; Baek SK; Park JH; Na W; Choi SO
    J Control Release; 2018 Sep; 286():460-466. PubMed ID: 30102940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Osmotic Pressure on the Stability of Whole Inactivated Influenza Vaccine for Coating on Microneedles.
    Choi HJ; Song JM; Bondy BJ; Compans RW; Kang SM; Prausnitz MR
    PLoS One; 2015; 10(7):e0134431. PubMed ID: 26230936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical evaluation of a novel microneedle device for intradermal delivery of an influenza vaccine: are all delivery methods the same?
    Levin Y; Kochba E; Kenney R
    Vaccine; 2014 Jul; 32(34):4249-52. PubMed ID: 24930715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
    Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
    Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and efficacy of the monovalent, trivalent and quadrivalent intranasal live attenuated influenza vaccines containing different pdmH1N1 strains.
    Yeolekar LR; Ganguly M; Tyagi P; Ingle NB; Stittelaar KJ; Waal L; Scorza FB; Mahmood K; Dhere RM
    Vaccine; 2018 Nov; 36(46):6944-6952. PubMed ID: 30322745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.